Sarepta Therapeutics, Inc. (NASDAQ:SRPT) PT Raised to $73.00 at Janney Montgomery Scott
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) had its price target boosted by analysts at Janney Montgomery Scott from $65.00 to $73.00 in a report released on Monday, The Fly reports. The firm currently has a “fair value” rating on the biotechnology company’s stock. Janney Montgomery Scott’s price target points to a potential upside of 68.16% from the stock’s previous close.
Several other analysts have also recently commented on the company. SunTrust Banks, Inc. upgraded Sarepta Therapeutics from a “hold” rating to a “buy” rating and upped their target price for the company from $30.00 to $30.97 in a report on Wednesday, April 5th. Vetr cut Sarepta Therapeutics from a “buy” rating to a “hold” rating and set a $36.86 price target on the stock. in a report on Monday, May 22nd. Cowen and Company restated a “buy” rating on shares of Sarepta Therapeutics in a report on Friday, April 28th. Robert W. Baird restated an “outperform” rating and set a $102.00 price target on shares of Sarepta Therapeutics in a report on Sunday, April 23rd. Finally, Nomura restated a “buy” rating and set a $84.00 price target on shares of Sarepta Therapeutics in a report on Tuesday, May 23rd. Eight research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $61.28.
Shares of Sarepta Therapeutics (SRPT) opened at 43.41 on Monday. The firm’s market capitalization is $2.39 billion. Sarepta Therapeutics has a one year low of $22.61 and a one year high of $63.73. The firm’s 50-day moving average is $33.69 and its 200 day moving average is $32.07.
Sarepta Therapeutics (NASDAQ:SRPT) last announced its earnings results on Wednesday, July 19th. The biotechnology company reported ($0.46) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.92) by $0.46. The company had revenue of $35.01 million during the quarter, compared to the consensus estimate of $22.52 million. During the same quarter in the previous year, the company earned ($1.19) earnings per share. The business’s revenue was up 350000.0% on a year-over-year basis. Equities research analysts predict that Sarepta Therapeutics will post ($0.94) earnings per share for the current year.
In related news, Director Edward M. Md Kaye sold 10,000 shares of the stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $41.00, for a total value of $410,000.00. Following the completion of the sale, the director now directly owns 62,471 shares of the company’s stock, valued at approximately $2,561,311. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Shamim Ruff sold 12,138 shares of the stock in a transaction on Friday, July 21st. The shares were sold at an average price of $42.97, for a total value of $521,569.86. Following the completion of the sale, the senior vice president now directly owns 27,312 shares of the company’s stock, valued at $1,173,596.64. The disclosure for this sale can be found here. Insiders sold a total of 78,056 shares of company stock valued at $3,224,208 over the last three months. 9.60% of the stock is currently owned by insiders.
Large investors have recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. raised its stake in Sarepta Therapeutics by 63.9% in the first quarter. Russell Investments Group Ltd. now owns 38,273 shares of the biotechnology company’s stock worth $1,133,000 after buying an additional 14,919 shares during the last quarter. Sigma Planning Corp raised its stake in shares of Sarepta Therapeutics by 7.8% in the first quarter. Sigma Planning Corp now owns 12,895 shares of the biotechnology company’s stock valued at $382,000 after buying an additional 930 shares in the last quarter. Columbus Circle Investors raised its stake in shares of Sarepta Therapeutics by 175.0% in the first quarter. Columbus Circle Investors now owns 34,027 shares of the biotechnology company’s stock valued at $1,007,000 after buying an additional 21,652 shares in the last quarter. Fox Run Management L.L.C. acquired a new stake in shares of Sarepta Therapeutics during the first quarter valued at about $388,000. Finally, Bank of Montreal Can raised its stake in shares of Sarepta Therapeutics by 1.0% in the first quarter. Bank of Montreal Can now owns 98,775 shares of the biotechnology company’s stock valued at $2,924,000 after buying an additional 996 shares in the last quarter. 73.09% of the stock is owned by institutional investors and hedge funds.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.